

## Supplementary Online Content

Karlawish J, Langa KM. Unfinished business in preventing Alzheimer disease.  
*JAMA Intern Med*. Published online October 17, 2016.  
doi:10.1001/jamainternmed.2016.6310.

### **eTable.** Current Alzheimer Disease Prevention Trials

This supplementary material has been provided by the authors to give readers additional information about their work.

Table. Current Alzheimer Disease Prevention Trials

Study Name and Sponsors	National Clinical Trial (NCT) Identifier	Study Drug(s)	Primary End Points
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer Disease Caused by a Genetic Mutation. (DIAN-TU) Eli Lilly and Company, Hoffmann-La Roche, Alzheimer Association, National Institute on Aging	NCT01760005	Gantenerumab, Solanezumab, antibodies to amyloid that reduce amyloid plaques	The Dominantly Inherited Alzheimer Disease Network Trial Unit (DIAN-TU) cognitive composite score
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss, also called Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4 Study) Eli Lilly and Company, National Institute on Aging	NCT02008357	Solanezumab, an antibody to amyloid that reduces amyloid plaques	Alzheimer Disease Cooperative Study–Preclinical Alzheimer Cognitive Composite (ADCS–PACC)
A Study of CAD106 and CNP520 Vs Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer Disease (Generation) Novartis Pharmaceuticals, National Institute on Aging	NCT02565511	CAD106, an antibody to amyloid that reduces amyloid plaques CNP520, a BACE inhibitor that reduces amyloid plaques	Time to diagnosis of mild cognitive impairment or dementia due to Alzheimer Disease and change in the Alzheimer Prevention Initiative Composite Cognitive (APCC) Test Score, design allows that either measure alone can establish evidence of efficacy.
An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for	NCT02569398	JNJ-54861911, a BACE inhibitor that reduces amyloid plaques	Preclinical Alzheimer Cognitive Composite (PACC)

Developing Alzheimer Dementia (Early) Janssen Research & Development			
A Study of Crenezumab Vs Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease (AD), Including a Placebo-Treated Noncarrier Cohort Banner Alzheimer Institute, National Institute on Aging, Genentech, Inc	NCT01998841	Crenezumab, an antibody to amyloid that reduces amyloid plaques	Alzheimer Prevention Initiative (API) Composite Cognitive Test total score

Abbreviation: BACE,  $\beta$ -secretase